We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Thermo, Nuclea Biotechnologies Collaborate to Develop Diabetes Markers
News

Thermo, Nuclea Biotechnologies Collaborate to Develop Diabetes Markers

Thermo, Nuclea Biotechnologies Collaborate to Develop Diabetes Markers
News

Thermo, Nuclea Biotechnologies Collaborate to Develop Diabetes Markers

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Thermo, Nuclea Biotechnologies Collaborate to Develop Diabetes Markers "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Monitoring the levels of these markers may be useful in predicting the response to therapy for Type 2 diabetes.

Nuclea has extensive experience in developing and commercializing biomarkers and clinical tests. The Thermo Fisher Scientific Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Center has successfully collaborated with numerous leading clinical researchers to apply mass spectrometry (MS) to biomarker discovery and its translation to high-throughput, quantitative methods. 

“We’ve already worked with the BRIMS Center to develop two other very important assays,” said Nuclea CEO, Patrick Muraca. “These assays have demonstrated the sensitivity, precision and robustness needed for high-throughput detection of clinically relevant isoforms of target proteins.”

“The real-world application of multiplexed MS-based methods to Type 2 diabetes presents an opportunity to advance research in this crucial area.” said Mary Lopez, director of the BRIMS Center, Thermo Fisher Scientific. “Nuclea’s proven ability to validate and develop routine assays means our collaboration can support research efforts.” 

Scientists from Nuclea and the BRIMS Center will develop multiplexed MS-based research methods that Nuclea will use to analyze donor plasma samples from Boston-based diabetes research collaborations. A proprietary platform that combines Thermo Scientific MSIA immuno-enrichment technology, TSQ Vantage or Quantiva triple quadrupole mass spectrometers and Pinpoint Software will be used for the collaborative work.

Advertisement